Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN 8 5 PH6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 W DEXTROSE 5 IN PLASTIC CONTAINER versus AMINOSYN 8 5 PH6.
AMINOSYN 3.5% W/ DEXTROSE 5% IN PLASTIC CONTAINER vs AMINOSYN 8.5% (PH6)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% w/ Dextrose 5% provides essential and non-essential amino acids for protein synthesis and dextrose for caloric support, aiding in nitrogen balance and maintenance of lean body mass in parenteral nutrition.
Aminosyn 8.5% (pH 6) provides a mixture of essential and nonessential amino acids for protein synthesis and nitrogen balance maintenance in patients unable to tolerate oral or enteral nutrition.
Intravenous infusion. Adult dose: 500-1000 mL per day, infused at a rate not exceeding 100 mL/hour, adjusted based on metabolic requirements and tolerance.
1-1.5 g amino acids/kg/day intravenously, typically 500 mL of a 8.5% solution (42.5 g amino acids) infused over 8-24 hours.
None Documented
None Documented
Not applicable as a single entity; amino acids and dextrose are endogenous substances. Metabolic half-life of infused amino acids ~10-30 min; dextrose ~15-20 min. Continuous infusion results in steady state.
Not applicable as a fixed value; elimination half-life of individual amino acids varies (minutes to hours) and is dependent on metabolic demand and renal function.
Renal excretion of amino acids and dextrose metabolites (CO2, water). Urea nitrogen accounts for ~80-90% of nitrogen excretion. Unchanged dextrose minimal (<1%). Biliary/fecal excretion negligible.
Primarily renal; elimination depends on metabolic utilization. Unused amino acids are deaminated and excreted as urea in urine (over 90%). Fecal elimination is negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution